Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04379752 · ClinicalTrials.gov registry record · NA
Cold Plasma to Treat Hair Loss
A NA study, sponsored by Dr. Peter C. Friedman.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
NCT04379752: Completed NA study, sponsored by Dr. Peter C. Friedman.
NCT04379752 is a NA study that has completed, run by Dr. Peter C. Friedman. The registered enrollment target is 14 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04379752, a NA study, has completed, sponsored by Dr. Peter C. Friedman.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
Study Summary
Self applied cold plasma activated medium used for androgenetic alopecia
Primary Outcome
Presence of hair growth is observed clinically. Evaluation may include photo comparison, hair count, trichoscopy
Interventions
- DEVICE Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2020-07-01 |
| Est. Completion | 2021-09-15 |
| Phase | NA |
What the finished NCT04379752 record still lists
NCT04379752 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment is the first listed.
NCT04379752 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04379752 about?
NCT04379752 is a clinical study titled "Cold Plasma to Treat Hair Loss". Self applied cold plasma activated medium used for androgenetic alopecia
What is the current status of trial NCT04379752?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2020-07-01. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT04379752?
The interventions under investigation include: Cold-atmospeheric pressure plasma activated aqueous-alcohol solution treatment (DEVICE).
Who is sponsoring clinical trial NCT04379752?
This trial is sponsored by Dr. Peter C. Friedman, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04379752's enrollment target sits among peer trials
14 1909th of 2000 higher than 90 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy